







MaioRegen Surgical technique

Free Hand



Mini Arthro Kit



Guarda il video

Shapes and Sizes*

| | |
|----------|-----------------------|
| 01600401 | 2,0 x 3,0 x 0,2 cm |
| 01600400 | 3,0 x 4,0 x 0,2 cm |
| 01600403 | Ø = 1,2 cm H = 0,2 cm |
| 01600405 | Ø = 1,5 cm H = 0,2 cm |
| 01600404 | Ø = 1,8 cm H = 0,2 cm |

MaioRegen Chondro+



| | |
|----------|-----------------------|
| 01600289 | 2,0 x 3,0 x 0,4 cm |
| 01600287 | 3,0 x 4,0 x 0,4 cm |
| 01600290 | Ø = 1,2 cm H = 0,4 cm |
| 01600282 | Ø = 1,5 cm H = 0,4 cm |
| 01600292 | Ø = 1,8 cm H = 0,4 cm |

MaioRegen Slim



| | |
|----------|-----------------------|
| 01600288 | 2,0 x 3,0 x 0,6 cm |
| 01600286 | 3,0 x 4,0 x 0,6 cm |
| 01600285 | Ø = 1,2 cm H = 0,6 cm |
| 01600275 | Ø = 1,5 cm H = 0,6 cm |
| 01600291 | Ø = 1,8 cm H = 0,6 cm |

MaioRegen Prime



* All products cleared for CE marketing (regulation EU 745/2017)
Not yet FDA approved



Fin-Ceramica Faenza Spa
via Granarolo 177/3 - 48018 Faenza RA, Italy
t +39 0546 645411 - f +39 0546 46763
info@finceramica.it - www.finceramica.it

SLOGAN II

MaioRegen

Biojoint System




Chondro+



Slim



Prime



A SYSTEM
TAILORED TO YOUR PATIENTS' NEEDS

MDU 006003-02-00

MaioRegen is a joint surface restoration system for the treatment of cartilage and osteochondral lesions, with a comprehensive range of solutions for all the pre-osteoarthritis stages, and supported by the highest level of scientific evidence.

Available in three different configurations, each for a specific indication, MaioRegen is a biomimetic resorbable device ready to use and easily implantable through a straight-forward surgical approach.

MaioRegen
Biojoint System
Chondro+



1+
Chondral lesions, with mild or no impairment of subchondral bone tissue.

MaioRegen
Biojoint System
Slim




2
Deep chondral and osteo-chondral lesions, with moderate bone impairment.

MaioRegen
Biojoint System
Prime



3
Osteo-chondral lesions with severe bone impairment.

Clear clinical indications based on the specific disease stage



PILOT CLINICAL STUDY

- Kon E. et al., AJSM, 2011 - 28 Patients - **2 years follow-up**
- Kon E. et al., AJSM, 2013 - 27 Patients - **5 years follow-up**
- Di Martino et al., AJSM 2021 - 24 Patients - **10 years follow-up**

Demographic and lesions data

- 28 Patients: 19 - 9
- Mean age (years ± SD): 35.3±10.2
- Average lesions size: 2.9 ± 1.3 cm²
- Lesions aetiology:
 - 6 OCD
 - 17 Microtraumatic/degenerative
 - 5 Traumatic


Complex cases

PREVIOUS SURGERIES
(20 PTS)



- 11** cartilage surgery
- 7** meniscal surger
- 4** ACL reconstruction
- 3** lateral release/patellar realignment
- 7** other

ASSOCIATED SURGERIES
(15 PTS)

- 7** lateral release/patellar realignment
- 4** osteotomy
- 2** meniscal surgery
- 1** ACL reconstruction
- 3** other



Clinical evaluation



From Results:

"The analysis of this population showed a statistically significant improvement of all clinical scores from the baseline to the final evaluation"


From Discussion:

"The main finding of this study is that this cell-free biomimetic osteochondral scaffold provided a **significant clinical improvement** in patients affected by symptomatic knee lesions, which **was stable over time**"

"A significant improvement of the clinical scores was observed at long-term follow-up after surgery, regardless of the number of previous or concurrent surgical procedures. Considering the variety of characteristics of this heterogeneous group of patients, **this series can closely represent the real clinical setting** of middleaged patients presenting with articular surface lesions who can obtain an overall benefit from this technique."


Results from a Level of Evidence I international RCT*

The study has been conducted to assess the benefit provided by MaioRegen Prime (tri-layer) scaffold.




Statistical significant improvement in IKDC Subjective Score for patients treated with MaioRegen from baseline to 2 years follow-up.

Evidence of MaioRegen superiority vs microfracture




Deep Osteochondral Lesions

Statistically significant MaioRegen superiority: +12.4 points vs Microfracture in change from baseline of IKDC Subjective score.



Sport Active Patients

Statistically significant MaioRegen superiority: +16.0 points vs Microfracture in change from baseline of IKDC Subjective score.



Osteochondritis Dissecans

Clinically relevant improvement of MaioRegen: +12.0 points vs Microfracture in change from baseline of IKDC Subjective score.

Clear Clinical Indications: RCT analysis in above sub-populations confirms the superiority of MaioRegen compared to microfracture.

* Kon et al., KSSTA, 2017